Jan. 24, 2011 (Marketwire) --
NEW YORK, NY -- (Marketwire) -- 01/24/11 -- Corporate Profile's financial website www.CPreports.com announces Ray Dirks Research's update of Pluristem Therapeutics, Inc. (NASDAQ: PSTI).
To view report go to: www.CPReports.com or http://www.cpreports.com/?p=831
CPReports.com features Gene Marcial, Ray Dirks and Goldman Small Cap Research. The website and newsletter provide readers and subscribers fresh, original, and highly informative ideas and market commentary that they won't get anywhere else. Content is focused on what is going on in the stock market and on Wall Street.
About Corporate Profile.com
www.CorporateProfile.com is a broadcasting website where Fashion meets Finance, merging two mainstream industries results in the unique platform for today's hottest tips and market info.
About Ray Dirks Research
Ray Dirks came to Wall Street with Goldman, Sachs & Co. in 1963 where he was established as the leading insurance stock analyst dealing with institutional investors and high-net worth investors both in the U.S. and internationally. Ray's research includes Healthcare Stocks and Special Situations. Ray has written two books, "The Great Wall Street Scandal" and "Heads You Win, Tails You Win," published by McGraw-Hill and Bantam Books respectively. He continues to provide research to institutions and individuals. Ray can be reached at: email@example.com
Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company's actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company's periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company's plans or expectation.